Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Liquid-based, Needle-Free Injector Market by Type (Jet, Spring, Laser, Vibration) and by End User (Hospitals, Clinics): Global Opportunity Analysis and Industry Forecast, 2023-2032

A02411

Pages: NA

Charts: NA

Tables: NA

Needle-free injection is a technology enables the delivery of drug through the skin, virtually nullifying the use of hypodermic needle. Liquid-based, needle-free injectors are used when the drug loaded in the injection is in the liquid form. This technology is highly beneficial for the evolving pharma industry. It is useful in mass immunization programmers, since it reduces the chances of needlestick injuries and other complications, including those arising due to multiple use of a single needle.

No complications with multiple use of single needle, low chances of developing needlestick injuries, and advancement in the technology for the development of liquid-based, needle-free injectors drive the growth of the global liquid-based, needle-free injectors market. However, certain technology-based challenges restrain the growth of the market.

The report segments the liquid-based, needle-free injector market on the basis of type, end user, and geography. Based on type, the market is categorized into jet, spring, laser, and vibration. By end user, it bifurcated into hospitals and clinic. Geographical breakdown and deep analysis of each of the aforesaid segments is included for North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Antares Pharma, Inc. and other companies operating in the Global Liquid-Based Needle-Free Injectors Market would be covered in the report.

Key Benefits

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global liquid based needle free injectors market.
  • In-depth analysis has been done in this report by constructing market estimations for the key market segments.
  • This report entails the detailed quantitative analysis of the current trends and future estimations which assists to identify the prevailing market opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • Exhaustive analysis of the global market by type helps to understand the types of liquid-based, needle-free injectors that are currently being used along with the variants that are expected to gain prominence in the future.
  • An in-depth analysis of current research and clinical developments within the market is provided with key factors that help to understand the behavior of the market

 Key Market Segments

  • By Type
    • Jet
    • Spring
    • Laser
    • Vibration
  • By End User
    • Hospitals
    • Clinics
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • European Pharma Group
  • Endo International
  • Bioject Medical Technologies
  • Antares Pharma
  • National Medical Products
  • Crossject SA
  • Medical International Technology
  • Valeritas

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Jet

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Spring

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Laser

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Vibration

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

  • CHAPTER 5: LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Clinics

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Liquid-based, Needle-free Injector Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Liquid-based, Needle-free Injector Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Liquid-based, Needle-free Injector Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Liquid-based, Needle-free Injector Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Liquid-based, Needle-free Injector Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Liquid-based, Needle-free Injector Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Liquid-based, Needle-free Injector Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Liquid-based, Needle-free Injector Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Liquid-based, Needle-free Injector Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Liquid-based, Needle-free Injector Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Liquid-based, Needle-free Injector Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Liquid-based, Needle-free Injector Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Liquid-based, Needle-free Injector Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Liquid-based, Needle-free Injector Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Liquid-based, Needle-free Injector Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Liquid-based, Needle-free Injector Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Liquid-based, Needle-free Injector Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Liquid-based, Needle-free Injector Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Liquid-based, Needle-free Injector Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Liquid-based, Needle-free Injector Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Liquid-based, Needle-free Injector Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Liquid-based, Needle-free Injector Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Liquid-based, Needle-free Injector Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Liquid-based, Needle-free Injector Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Liquid-based, Needle-free Injector Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Antares Pharma

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Bioject Medical Technologies

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Medical International Technology

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Endo International

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. National Medical Products

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Valeritas

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. European Pharma Group

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Crossject SA

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR JET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR SPRING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR LASER, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR VIBRATION, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR CLINICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. NORTH AMERICA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 13. U.S. LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 14. U.S. LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 15. CANADA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 16. CANADA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 17. MEXICO LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 18. MEXICO LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. EUROPE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY REGION, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 22. FRANCE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 23. FRANCE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. GERMANY LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 25. GERMANY LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. ITALY LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 27. ITALY LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. SPAIN LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 29. SPAIN LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. UK LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 31. UK LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. RUSSIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 33. RUSSIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. REST OF EUROPE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 35. REST OF EUROPE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. ASIA-PACIFIC LIQUID-BASED, NEEDLE-FREE INJECTOR, BY REGION, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 39. CHINA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 40. CHINA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. JAPAN LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 42. JAPAN LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. INDIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 44. INDIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. SOUTH KOREA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 46. SOUTH KOREA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. AUSTRALIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 48. AUSTRALIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. THAILAND LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 50. THAILAND LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. MALAYSIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 52. MALAYSIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 53. INDONESIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 54. INDONESIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. LAMEA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY REGION, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 60. BRAZIL LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 61. BRAZIL LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. SOUTH AFRICA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH AFRICA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. SAUDI ARABIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 65. SAUDI ARABIA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 66. UAE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 67. UAE LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. ARGENTINA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 69. ARGENTINA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. REST OF LAMEA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 71. REST OF LAMEA LIQUID-BASED, NEEDLE-FREE INJECTOR, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. ANTARES PHARMA: KEY EXECUTIVES
  • TABLE 73. ANTARES PHARMA: COMPANY SNAPSHOT
  • TABLE 74. ANTARES PHARMA: OPERATING SEGMENTS
  • TABLE 75. ANTARES PHARMA: PRODUCT PORTFOLIO
  • TABLE 76. ANTARES PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 77. BIOJECT MEDICAL TECHNOLOGIES: KEY EXECUTIVES
  • TABLE 78. BIOJECT MEDICAL TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 79. BIOJECT MEDICAL TECHNOLOGIES: OPERATING SEGMENTS
  • TABLE 80. BIOJECT MEDICAL TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 81. BIOJECT MEDICAL TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. MEDICAL INTERNATIONAL TECHNOLOGY: KEY EXECUTIVES
  • TABLE 83. MEDICAL INTERNATIONAL TECHNOLOGY: COMPANY SNAPSHOT
  • TABLE 84. MEDICAL INTERNATIONAL TECHNOLOGY: OPERATING SEGMENTS
  • TABLE 85. MEDICAL INTERNATIONAL TECHNOLOGY: PRODUCT PORTFOLIO
  • TABLE 86. MEDICAL INTERNATIONAL TECHNOLOGY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. ENDO INTERNATIONAL: KEY EXECUTIVES
  • TABLE 88. ENDO INTERNATIONAL: COMPANY SNAPSHOT
  • TABLE 89. ENDO INTERNATIONAL: OPERATING SEGMENTS
  • TABLE 90. ENDO INTERNATIONAL: PRODUCT PORTFOLIO
  • TABLE 91. ENDO INTERNATIONAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. NATIONAL MEDICAL PRODUCTS: KEY EXECUTIVES
  • TABLE 93. NATIONAL MEDICAL PRODUCTS: COMPANY SNAPSHOT
  • TABLE 94. NATIONAL MEDICAL PRODUCTS: OPERATING SEGMENTS
  • TABLE 95. NATIONAL MEDICAL PRODUCTS: PRODUCT PORTFOLIO
  • TABLE 96. NATIONAL MEDICAL PRODUCTS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. VALERITAS: KEY EXECUTIVES
  • TABLE 98. VALERITAS: COMPANY SNAPSHOT
  • TABLE 99. VALERITAS: OPERATING SEGMENTS
  • TABLE 100. VALERITAS: PRODUCT PORTFOLIO
  • TABLE 101. VALERITAS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. EUROPEAN PHARMA GROUP: KEY EXECUTIVES
  • TABLE 103. EUROPEAN PHARMA GROUP: COMPANY SNAPSHOT
  • TABLE 104. EUROPEAN PHARMA GROUP: OPERATING SEGMENTS
  • TABLE 105. EUROPEAN PHARMA GROUP: PRODUCT PORTFOLIO
  • TABLE 106. EUROPEAN PHARMA GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. CROSSJECT SA: KEY EXECUTIVES
  • TABLE 108. CROSSJECT SA: COMPANY SNAPSHOT
  • TABLE 109. CROSSJECT SA: OPERATING SEGMENTS
  • TABLE 110. CROSSJECT SA: PRODUCT PORTFOLIO
  • TABLE 111. CROSSJECT SA: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET SEGMENTATION
  • FIGURE 2. GLOBAL LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET
  • FIGURE 3. SEGMENTATION LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALLIQUID-BASED, NEEDLE-FREE INJECTOR MARKET
  • FIGURE 11. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR JET, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR SPRING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR LASER, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR VIBRATION, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET SEGMENTATION, BY BY END USER
  • FIGURE 17. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 18. LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET FOR CLINICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 20. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 22. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 23. COMPETITIVE DASHBOARD
  • FIGURE 24. COMPETITIVE HEATMAP: LIQUID-BASED, NEEDLE-FREE INJECTOR MARKET
  • FIGURE 25. TOP PLAYER POSITIONING, 2024
  • FIGURE 26. ANTARES PHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 27. ANTARES PHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 28. ANTARES PHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 29. BIOJECT MEDICAL TECHNOLOGIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 30. BIOJECT MEDICAL TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 31. BIOJECT MEDICAL TECHNOLOGIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 32. MEDICAL INTERNATIONAL TECHNOLOGY: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 33. MEDICAL INTERNATIONAL TECHNOLOGY: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 34. MEDICAL INTERNATIONAL TECHNOLOGY: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 35. ENDO INTERNATIONAL: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 36. ENDO INTERNATIONAL: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 37. ENDO INTERNATIONAL: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 38. NATIONAL MEDICAL PRODUCTS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 39. NATIONAL MEDICAL PRODUCTS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 40. NATIONAL MEDICAL PRODUCTS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 41. VALERITAS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 42. VALERITAS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 43. VALERITAS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 44. EUROPEAN PHARMA GROUP: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 45. EUROPEAN PHARMA GROUP: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 46. EUROPEAN PHARMA GROUP: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 47. CROSSJECT SA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 48. CROSSJECT SA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 49. CROSSJECT SA: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Liquid-based, Needle-Free Injector Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved